PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Iron oxide nanoparticles present a promising alternative to conventional energy deposition-based tissue therapies. The
success of such nanoparticles as a therapeutic for diseases like cancer, however, depends heavily on the particles' ability
to localize to tumor tissue as well as provide minimal toxicity to surrounding tissues and key organs such as those
involved in the reticuloendothelial system (RES). We present here the results of a long term clearance study where mice
injected intravenously with 2 mg Fe of 100 nm dextran-coated iron oxide nanoparticles were sacrificed at 14 and 580
days post injection. Histological analysis showed accumulation of the nanoparticles in some RES organs by the 14 day
time point and clearance of the nanoparticles by the 580 day time point with no obvious toxicity to organs. An additional
study reported herein employs 20 nm and 110 nm starch-coated iron oxide nanoparticles at 80 mg Fe/kg mouse in a
size/biodistribution study with endpoints at 4, 24 and 72 hours. Preliminary results show nanoparticle accumulation in
the liver and spleen with some elevated iron accumulation in tumoral tissues with differences between the 20 nm and the
110 nm nanoparticle depositions.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Jennifer A. Tate, Alicia A. Petryk, Andrew J. Giustini, P. Jack Hoopes, "In vivo biodistribution of iron oxide nanoparticles: an overview," Proc. SPIE 7901, Energy-based Treatment of Tissue and Assessment VI, 790117 (23 February 2011); https://doi.org/10.1117/12.876414